Used in cancer immunotherapy research to modulate the PD-1/PD-L1 pathway, enhancing T-cell activation and anti-tumor immune responses. Shows potential in developing treatments for solid tumors and hematological malignancies by overcoming immune evasion mechanisms. Investigated for combination therapies with other immune checkpoint inhibitors to improve therapeutic efficacy.